Hi Jason, you should have been given a color Decipher report with the findings for your specific cancer.
If you weren't given a copy of your Decipher report, you should request it from the doctor who ordered the test. It's an important document you should keep in your records.
To see a Sample Report, click on
this link.
Then to download the appropriate report, click on the
Leftmost: Decipher
BIopsy, which is the test that was done on your biopsied tissue.
Your report will differ from the Sample Report as to the numbers, but the
blue/orange/red scale on the left still applies: Decipher scores range from 0.0 to a maximum of 1.0, The high-risk (red) zone starts a score of 0.6 and goes up to 1.0. You mentioned that your score was 0.61, which as you can see is at the low end of the high-risk category. Each score corresponds to a 5- and 10-year risk of having metastatic disease. You can study your personal report for explanations of your numbers, but the bottom line, to the best of my knowledge, is that a guy who gets back a high Decipher score needs to come off AS and seek primary treatment in the coming weeks.
IMO, you should definitely appeal the insurance decision not to cover your test:your high-risk result attests to the test's necessity. If you should lose the appeal, contact the Decipher test maker, Veracyte--you may be able to work out a reduced fee (I was able to).
Until the advent of genomic testing, it was thought that there was a direct correspondence between Gleason score and tumor aggressiveness, or the pr
opensity to metastasize. We now now that you can be low-, average-, or high risk for metastasis with any Gleason score. The only thing that changes are the percentages of men in any one category, which skews toward more men in the average- and high- risk groups as the Gleason score increases.
Unlike DNA testing, which tells you if you have genetic (familial) gene mutations that increase your risk of getting certain diseases/cancers, genomic tests like Decipher look at your specific cancer's RNA, so it's not telling you about
conditions you may or may not get at some point, but rather about
the cancer that you now have.
Keep in mind that primary treatment has the potential to put even high-risk cancer in the rear-view mirror. Obviously the chances of this go up considerably if the cancer is still prostate-confined at the time of primary treatment.
Djin